RELIEVE was a 24-week, observational, prospective, international cohort study in outpatients with MDD initiating vortioxetine treatment at their physician’s discretion in routine care settings (NCT03555136).
Posters
Posters
The relationship between anhedonia severity and the clinical and humanistic burden among patients with MDD is poorly understood.
Posters
This retrospective cohort study used an insurer’s claims database. Patients (≥18 years) were included based on newly diagnosed MDD (ICD-10) recorded by a PCP or a Psychiatric provider (PSY) from 1/1/2019 to 12/31/2021, and followed for 12 months.